Trade Corcept Therapeutics Inc - CORT CFD

Corcept Company profile

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the steroid hormone cortisol. The Company has marketed the cortisol modulator Korlym in the United States for the treatment of patients with a form of hypercortisolism known as endogenous Cushing’s syndrome. Cortisol activity can be modulated effectively by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s active ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its portfolio of selective cortisol modulators consists of four structurally distinct series, including relacorilant, exicorilant and miricorilant. These compounds bind to GR but not the progesterone, estrogen or androgen receptors.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Corcept Therapeutics Incorporated revenues increased 3% to $366M. Net income increased 6% to $112.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Research and development - Balancing val decrease of 4% to $99.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from $0.92 to $0.97.

Equity composition

Common Stock $.001 Par, 3/11, 140M auth., 83,968,540 issd., Insiders control 13.80%. IPO 4/14/04,4.5M shares @ $12 by USBancorp.